Avant Technologies Inc. (OTCQB:AVAI) (”Avant” or the “Company”), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease ...
Q4 2024 Management View CEO Punit Dhillon highlighted significant progress with the clinical development of nimacimab, including the completion of patient enrollment for the CBeyond Phase IIa trial ...
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 4 of its ...
Ainnova has hired an ophthalmologist, who is assisting in drafting the requirements for the clinical trial protocol that the Company's Contract Research Organization (CRO), Fortrea, has requested.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results